· Ovid Therapeutics
Dr. Jeremy Levin: Why Biotech Is Not Big Pharma
with Dr Jeremy Levin, Founder — Ovid Therapeutics

About 70% of new drugs originate in biotechnology, not big pharma, says Dr. Jeremy Levin, founder of Ovid Therapeutics. Dr. Levin emphasizes the critical role of biotech in drug innovation, noting that 70% of new drugs originate from this sector. He also addresses the growing distrust in the industry, attributing it to factors like politicization and misinformation, and advocates for biotech to be recognized as a national strategic asset to restore public confidence.
Related coverage
Dr. Jeremy Levin: Why Biotech Is Not Big Pharma
Biotech Leader Dr. Jeremy Levin Discusses Industry's Unique Role and Challenges
In a recent episode of the Health Policy Podcast, Dr. Jeremy Levin, founder of Ovid Therapeutics and author of "Biotech in the Balance," shared insights on the biotechnology sector's distinct role in healthcare and the challenges it faces amid rising public distrust. Levin, who has over three decades of experience in the industry, spoke with host Bryan Hyde about the evolution of biotech, its relationship with big pharmaceutical companies, and the need for renewed trust in science.
Dr. Levin began by outlining his extensive background, which includes a PhD focused on DNA thermodynamics and a medical degree from Cambridge University. His career spans various roles in biotech and pharmaceuticals, including leadership positions at Genzyme, Novartis, and Bristol Myers Squibb. He emphasized the importance of innovation in biotechnology, stating that 70% of new drugs are developed by small biotech companies rather than large pharmaceutical firms.
"The industry as a whole is immensely productive," Levin said. He noted that while biotech companies often face high failure rates, their commitment to innovation is crucial for advancing medical science. He described these companies as "the engine that you don't see," highlighting their significant contributions to healthcare despite being largely unknown to the general public.
Levin attributed the public's misunderstanding of biotech to a historical shift in perception. He explained that while pharmaceutical companies were once seen as heroes for curing diseases like polio and measles, incidents such as the controversial claims linking vaccines to autism have fueled skepticism. This skepticism, combined with rising drug prices and political rhetoric, has led to a conflation of biotech and big pharma in the public's mind.
"People confuse biotech with pharma," Levin explained. "When they see pharma, they think about inflated drug prices and corporate greed." He argued that this perception undermines the critical innovations that biotech companies are bringing to market.
The conversation also touched on the impact of the COVID-19 pandemic on public trust in science. Levin noted that while the rapid development of vaccines was a testament to decades of research, misinformation and conspiracy theories surrounding the vaccines further eroded public confidence. He lamented the politicization of science, stating that "the biotech industry became a political piñata."
To address these challenges, Levin proposed that biotech should be recognized as a national strategic asset, akin to defense or housing. He emphasized the need for policymakers to support the industry through stable funding and clear communication channels. "If we don't make biotech a priority, we risk losing our competitive edge," he warned.
On the industry side, Levin outlined ten commitments that biotech companies should adopt to rebuild trust. These include increasing transparency, focusing on patient-centric innovation, and actively countering misinformation. He stressed that biotech firms must communicate their successes and challenges more effectively to the public.
Levin's book, "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust," aims to shed light on these issues and advocate for a stronger, more transparent biotech sector. The book is set to be released on May 19 and will be available on platforms like Amazon and Kindle.
As the conversation concluded, Levin reiterated the importance of collaboration between biotech and pharmaceutical companies. He acknowledged that while they serve different roles, both sectors are essential for advancing healthcare and improving patient outcomes.
The interview highlighted the critical need for a renewed commitment to trust and transparency in the biotech industry, especially as it navigates a complex landscape of public perception and political scrutiny.
Interview Q&A
Q&A: Dr. Jeremy Levin: Why Biotech Is Not Big Pharma
Health Policy Podcast Q&A with Dr. Jeremy Levin
Q: Can you tell us about your background?
A: I have a technical background in biotechnology, starting with my work on the thermodynamics of DNA supercoiling. After earning my PhD, I pursued a medical degree at Cambridge, which deepened my understanding of patient care. I became involved in the biotechnology industry over 30 years ago.
Q: What is biotechnology, and how does it differ from big pharmaceutical companies?
A: Biotechnology focuses on using living systems and organisms to develop products, while big pharmaceutical companies primarily distribute established medicines. Biotech companies are typically smaller and more innovative, often partnering with larger firms for late-stage development.
Q: How has biotechnology evolved since its inception?
A: The biotechnology revolution began in 1973 with the work of scientists Cohen and Boyer, leading to the establishment of Genentech. Today, there are about 1,000 biotech companies in the U.S., contributing significantly to new drug development.
Q: What percentage of new drugs come from biotech companies?
A: Approximately 70% of new drugs come from biotech companies, highlighting their critical role in innovation within the pharmaceutical industry.
Q: Why is there a growing distrust in the biotech and pharmaceutical industries?
A: Distrust has grown due to several factors, including the fallout from the autism-vaccine controversy and the perception that pharmaceutical companies prioritize profits over patient care. Events like Martin Shkreli's price hikes on old drugs have further fueled this distrust.
Q: What impact did COVID-19 have on public perception of biotech?
A: During COVID-19, despite the rapid development of vaccines, misinformation and myths about the vaccines contributed to distrust in the biotech industry. This was exacerbated by the politicization of the pandemic response.
Q: What steps can be taken to restore trust in biotech?
A: Restoring trust requires policymakers to recognize biotech as a national strategic asset and ensure predictable regulatory processes. Biotech companies must also commit to transparency and prioritize patient-focused innovation.
Q: What commitments do you suggest for biotech companies?
A: Biotech companies should focus on transparency, a genuine commitment to patients, and actively counter misinformation. They should also drive innovation not just in drug development but in manufacturing processes.
Q: How can the relationship between biotech and big pharma be improved?
A: Big pharmaceutical companies should clearly communicate their roles in drug development and innovation, emphasizing their partnerships with biotech firms. They need to shift the narrative from profit-driven motives to patient-centered care.
Q: What is the significance of your book, "Biotech in the Balance"?
A: The book addresses the challenges facing the biotech industry in an age of distrust and outlines strategies for revitalizing innovation and public confidence in the sector.
Q: When will your book be available, and where can it be found?
A: "Biotech in the Balance" will be available on May 19 and can be found on Amazon, including an audiobook version and a Kindle edition.
Q: What final thoughts do you have on the future of biotech?
A: The future of biotech is promising, but it requires a concerted effort from both policymakers and industry leaders to foster innovation and rebuild public trust.
Key questions
What is the main focus of Dr. Jeremy Levin's book?
Dr. Jeremy Levin's book, 'Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust,' focuses on the importance of the biotech industry, its innovations, and the need to restore trust in the sector amidst growing skepticism and politicization.
How has the biotech industry changed since its inception?
Since its inception in the 1970s, the biotech industry has evolved from a small number of companies focused on innovation to a robust field with around 1,000 companies contributing significantly to new drug development, with 70% of new drugs coming from biotech.
What are some reasons for the current distrust in the biotech and pharmaceutical industries?
Distrust in the biotech and pharmaceutical industries has grown due to several factors, including high drug prices, misinformation about vaccines, and the perception that these companies prioritize profit over patient care.
What does Dr. Levin suggest to restore trust in biotech?
Dr. Levin suggests that biotech should be recognized as a national strategic asset, and that both policymakers and companies need to commit to transparency, patient-centric practices, and effective communication to rebuild trust.
What role do large pharmaceutical companies play in the biotech industry?
Large pharmaceutical companies partner with biotech firms, providing resources for late-stage development and distribution, while biotech firms focus on innovation and developing new therapies.
What is the impact of misinformation on public perception of biotech?
Misinformation, particularly regarding vaccines and drug pricing, has led to public skepticism and confusion, causing people to conflate biotech with pharmaceutical companies and their practices.
How can the biotech industry improve its communication with the public?
The biotech industry can improve communication by being transparent about their processes, actively addressing misinformation, and engaging with the public to explain their innovations and the benefits they bring to healthcare.
Key takeaways
- “70% of the new drugs come from biotech.”
- “Distrust starts to creep. And that is where the real problem starts for the industry.”
- “We need to make biotech a national strategic asset, just like housing, just like defense.”
- “If we don't, none of the things that I've just talked about, the building of science, the establishment of a rigorous world-class FDA, will ever be put into place.”
- “Fifty percent of all people taking drugs stop them at the end of the first year.”
- “We have commitments. If we do those, they respond to, one, transparency; two, articulating genuine commitment to patients.”
About the guest

Founder — Ovid Therapeutics
Dr. Jeremy M. Levin is a physician-scientist and biotech leader who serves as the executive chairman of Ovid Therapeutics, former CEO of Teva Pharmaceuticals, and past chairman of the Biotechnology Innovation Organization (BIO).
Full transcript
Show full transcriptHide transcript
Filed under
Related episodes
- Patient's Rising's Terry Wilcox: The gap between FDA approval and patient access for Alzheimer’s treatments
- The Hidden Drivers of Hospital Consolidation
- Why the Affordable Care Act isn't delivering affordability, according to Nathan Benefield
- Steve Cortes: Why America Needs the Make America Healthy Again Movement
